"The primary efficacy endpoint will be trajectory of PaO2/FiO2 ratio (a measure of hypoxemia, a low level of oxygen in the blood caused by compromised lung function) by Day 7. Safety and tolerability up to Day 28 will also be a primary endpoint."
Fast readout here.
and data for CRS/ Sepsis too and implications for IPF undergoing Potency tests currently at Monash.
Ann: First Patient Enrolled in Cynata MEND Clinical Trial, page-4
-
- There are more pages in this discussion • 180 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.010(5.56%) |
Mkt cap ! $34.32M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 19.5¢ | 18.0¢ | $9.062K | 48.88K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 104632 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 3 | 1 |
View Market Depth
| Last trade - 14.37pm 12/09/2024 (20 minute delay) ? |
| CYP (ASX) Chart |